SCHEMBL21664009

SCHEMBL21664009

C=CCOC(=O)c1csc(-c2ccccn2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.45
CYP3A4 P08684 2/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
CYP2C19 P33261 1/20 0.42
TLR7 Q9NYK1 5/20 0.41
RAB9A P51151 6/20 0.40
HSD17B10 Q99714 3/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPT P10636 3/20 0.40
PKM P14618 2/20 0.40
KDM4E B2RXH2 2/20 0.40
GFER P55789 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
TSHR P16473 1/20 0.40
NPC1 O15118 4/20 0.39
POLB P06746 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31341038 0.84 LMNA (0.62) PDE10ALMNACYP1A2CYP2C19TLR7
SCHEMBL2436892 0.84 LMNA (0.62) PDE10ALMNACYP1A2CYP2C19TLR7
SCHEMBL21639115 0.82 CYP3A4 (0.40) CYP3A4CYP1A2CYP2C9HPGDCYP2C19
SCHEMBL21689117 0.82 ALDH1A1 (0.42) CYP3A4CYP1A2CYP2C9HPGDCYP2C19
SCHEMBL1397897 0.80 CYP3A4 (0.59) CYP3A4LMNAHSD17B10ALDH1A1PKM
SCHEMBL11003858 0.80 HPGD (0.51) CYP3A4LMNACYP1A2CYP2C9HPGD
SCHEMBL2549198 0.79 MAOA (0.59) PDE10ALMNATLR7RAB9AHSD17B10
SCHEMBL30457946 0.78 CYP3A4 (0.38) CYP3A4CYP1A2CYP2C9HPGDCYP2C19
SCHEMBL2553489 0.76 HPGDS (0.61) PDE10ALMNATLR7RAB9AHSD17B10
SCHEMBL2550713 0.76 PDE10A (0.57) PDE10ALMNATLR7RAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319347-B2 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound FUJIFILM CORPORATION (JP) 2022-05-03 US disclosed
US-20200040039-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND FUJIFILM CORPORATION (JP) 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200040039-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND VIP, NPPA, NGLY1 PDE10A 768/4885CYP3A4 4807/4885LMNA 3026/4885
US-11319347-B2 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound VIP, NPPA, NGLY1 PDE10A 768/4885CYP3A4 4807/4885LMNA 3026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.